Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Giatromanolaki A. et al, (2020), Br J Cancer
CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.
Felce SL. et al, (2020), Front Oncol, 10
ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile.
Favara DM. et al, (2019), Metabolites, 9
Development of therapeutic anti-JAGGED1 antibodies for cancer therapy.
Masiero M. et al, (2019), Mol Cancer Ther
ADGRL4/ELTD1 is a highly conserved angiogenesis-associated orphan adhesion GPCR that emerged with the first vertebrates and comprises 3 evolutionary variants.
Favara DM. et al, (2019), BMC Evol Biol, 19
FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.
Giatromanolaki A. et al, (2019), Exp Lung Res, 1 - 8
The oncogenic roles of TRPM ion channels in cancer
Wong KK. et al, (2019), Journal of Cellular Physiology
Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.
Boullosa LF. et al, (2018), Oncotarget, 9, 3853 - 3866
DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas.
Loo SK. et al, (2017), Pathology, 49, 731 - 739
TRPM4 expression is associated with activated B cell subtype and poor survival in diffuse large B cell lymphoma.
Loo SK. et al, (2017), Histopathology, 71, 98 - 111
Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.
Li D. et al, (2017), Cancer Res, 77, 2699 - 2711
The significance of FOXP1 in diffuse large B-cell lymphoma.
Gascoyne DM. and Banham AH., (2017), Leuk Lymphoma, 58, 1037 - 1051
Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.
Gascoyne DM. et al, (2017), Endocrinology, 158, 503 - 515
Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients.
Ait-Tahar K. et al, (2017), Adv Hematol, 2017
Therapeutic Antibodies against Intracellular Tumor Antigens.
Trenevska I. et al, (2017), Front Immunol, 8
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Wong KK. et al, (2016), Oncotarget, 7, 52940 - 52956
N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.
Brown PJ. et al, (2016), Haematologica, 101, 861 - 871